Trial Profile

A Phase II/III trial of JR-031 for the treatment of steroid-refractory acute Graft-versus-Host disease after hematopoietic stem cell transplantion

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 22 Feb 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

04 Sep 2015 According to Mesoblast media release, the Committee on Regenerative Medicine Products and Biological Technology of Pharmaceutical Affairs and Food Sanitation Council of the Japan Ministry of Health, Labour and Welfare has recommended for approval the allogeneic mesenchymal stem cell-based regenerative medicine product JR-031 (remestemcel-L).
05 Jun 2014 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
22 Nov 2012 Actual initiation date changed from 1 Jan 2012 to 1 Nov 2011 as reported by University Hospital Medical Information Network - Japan.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com